Actimmune Osteopetrosis Approval Doubles Potential Market To 800 Patients
Executive Summary
Approval of InterMune's supplemental indication for Actimmune for the treatment of osteopetrosis received Feb. 10 could double the number of patients in which the interferon gamma-1b therapy may be used.